Nanotherapeutics Initiates Phase 2 Clinical Trial for Treatment of Post Traumatic Stress Disorder
Nanotherapeutics is assessing the safety of its drug for treating PTSD – post traumatic stress disorder. About 300,000 veterans of the recent wars are estimated to be affected by PTSD or major depression.
Alachua, FL (PRWEB) May 23, 2012
Nanotherapeutics, Inc., today announced initiation of a Phase 2 clinical trial for the treatment of Post Traumatic Stress Disorder (PTSD) with PRX-3140. The trial is a single-site, open label pilot study to assess safety for use in adult subjects with PTSD. The trial design will also evaluate the efficacy of PRX-3140 in reducing PTSD and mood-related symptoms and reducing cognitive symptoms (e.g., reduced choice reaction time, speed of information processing, attention, learning and memory, executive functioning) compared to baseline. Principal investigator for the trial is Elias Sarkis, MD, of Gainesville, FL.
Once referred to as shell shock or battle fatigue syndrome and now associated with “Gulf War Syndrome”, PTSD is a serious condition that can develop after experiencing, seeing or learning about an event that causes intense fear, helplessness or horror in which serious physical harm occurred or was threatened.
It is estimated that 300,000 veterans of the Iraq and Afghanistan wars are likely to suffer from either PTSD or major depression. While there is no cure for PTSD, early identification and treatment of PTSD symptoms may lessen the severity of the condition and improve the overall quality of life for veterans suffering from this condition.
PRX-3140 is a potent and selective partial agonist of the serotonin subtype 4 receptor (5-HT4R). Secretion of acetylcholine (Ach) has been shown in vitro to be enhanced by stimulation of the 5-HT4R, and in vivo animal studies have demonstrated that PRX-3140 can increase brain concentrations of ACh. The cholinergic neurotransmitter system plays an important role in memory and other cognitive functions.
A critical breakdown in working memory produces difficulties with concentration and memory which underlies PTSD. Alterations in the cholinergic system will influence performance on cognitive tasks involving memory function, and may therefore affect the conditions for which impaired cognitive performance is a defining clinical characteristic of PTSD.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/5/prweb9534972.htm